Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
OHSU Knight Cancer Institute
Eastern Cooperative Oncology Group
Global BioClinical
University of Southern California
University of Southern California